Symptom status, medication adherence, and quality of life in HIV disease

Journal of Hospice and Palliative Nursing

Volumn 7, Issue 3, 2005, Pages 129-138

  Corless, Inge B ^a   Nicholas, Patrice K ^a   Davis, Sheila M ^a   Dolan, Sara A ^a   McGibbon, Chris A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NEW BRUNSWICK   (Canada)

Author keywords

Antiretroviral adherence; Hiv aids; Medication adherence; Quality of life; Symptom status

Indexed keywords

EID: 28044469275     PISSN: 15222179     EISSN: 15390705     Source Type: Journal    
DOI: 10.1097/00129191-200505000-00005     Document Type: Article

References (75)

1. Nokes KM, Bakken S. Issues associated with measuring symptom status. J N Y State Nurses Assoc. 2003; 33:17-21.
2. University of California, San Francisco School of Nursing Symptom Management Faculty Group. A model for symptom management. Image J Nurs Sch. 1994; 26:272-276.
3. Daar ES, Cohen C, Sherer R, Smith K. Improving adherence to antiretroviral therapy. AIDS Read. 2003;13(2):85-86, 88-90.
4. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr. 2002;31 (suppl 3):S98-S102.
5. Wood E, Hogg R, Yip B. The impact of baseline CD4 T-cell and adherence on rates of disease progression among HIV-infected patients initiating triple drug therapy. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Wash. Abstract 465.
6. Harrigan R, Montaner JSG. A perspective on HIV-1 drug resistance. International AIDS Society Newsletter. 2001; 18:6-8.
7. Knobel AJ, Casado JL, Collazos J, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002; 16(4):605-613.
8. Raboud JM, Harris M, Rae S, Montaner JS. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med. 2002; 3(2):118-124.
9. Ingersoll K. Influences on adherence to HIV medication. In: Meeting of the Association of Nurses in Aids Care. November 9, 2002; San Francisco, Calif.
10. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA. 2002;288: 2868-2879.
11. Da Silveira VL, Drachler ML, Leite JC, Pinheiro CA. Characteristics of HIV antiretroviral regimen and treatment adherence. Braz J Infect Dis. 2003; 7:194-201.
12. Sipes CS, Jones SG, Kauschinger E, et al. Tolerability of Medication Assessment (TOMA) Instrument demonstrates correlation between severity of side effects, impact on activities of daily living (ADLs), and perceived quality of life (QOL). In: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. WePeB5681.
13. Corless IB, Nicholas PK, Davis SM, Dolan SE, McGibbon CA. Symptom status and medication adherence in HIV disease. In: XIV International AIDS Conference. July 7-12, 2002; Barcelona, Spain. MoPeB3198.
14. Tsasis P. Adherence assessment to highly active antiretroviral therapy. AIDS Patient Care STDs. 2001; 15(3):109-115.
15. Elion R. The role of patient-provider Relationship. In: Adherence Continuum: Defining the role of the regimen and the healthcare provider. November 12, 1999; San Diego, Calif. 1.
16. Dorz S, Lazzarini L, Cattelan A, et al. Evaluation of adherence to antiretroviral therapy in Italian patients. AIDS Patient Care STDS. 2003; 17(1):33-41.
17. Molassiotis A, Nahas-Lopez V, Chung WY, Lam SW, Li CK, Lau TF. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS. 2002; 13(5):301-310.
18. Pinheiro CA, de-carvalho-Leite JC, Drachler ML, Silveira VL. Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: a cross-sectional study in Southern Brazil. Braz J Med Biol Res. 2002; 35(10):1173-1181.
19. Martin-Sanchez V, Ortega-Valin L, Perez-Simon MD, et al. Factors predicting lack of adherence to highly active antiretroviral treatment. Enferm Infec Microbiol Clin. 2002; 20(10):491-497.
20. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002; 17(10):756-765.
21. Simoni JM, Frick PA, Lockhart D, Liebovitz D. Mediators of social support and antiretroviral adherence among an indigent population in New York City. AIDS Patient Care STDS. 2002; 16(9):431-439.
22. Wagner GJ. Predictors of antiretroviral adherence as measured by self report, electronic monitoring and medication diaries. AIDS Patient Care. 2002; 16(12):599-608.
23. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001; 28(5):445-449.
24. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001; 2(1):38-45.
25. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31 (suppl 3):S123-S127.
26. Ka’opua L. Treatment adherence to an antiretroviral regime: the lived experience of Native Hawaiians and kokua. Pac Health Dialogue. 2001; 8(2):290-298.
27. O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Defic Syndr. 2003; 34:407-414.
28. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther. 2002; 7(3):185-193.
29. Guaraldi G, Murri R, Orlando G, et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials. 2003; 4(2):99-106.
30. Carrieri MP, Chesny MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med. 2003; 10(1):1-14.
31. Pratt RJ, Robinson N, Loveday HP, et al. Adherence to antiretroviral therapy: appropriate use of self-reporting in clinical practice. HIV Clin Trials. 2001; 2(2):146-159.
32. Starace F, Abrescia N, Angarano G, et al. Adherence as a gender issue: psychosocial factors influencing antiretroviral adherence in HIV- seropositive women. In: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. WePeB5854.
33. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S136-S139.
34. Eversly R, Egorin M. Gender differences in depression and adherence among people living with HIV. In: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. B10507.
35. Perry S, Bangsberg DB, Charlebois ED, et al. Depressive symptoms predict adherence, treatment duration and survival in an urban poor cohort. In: XIV International AIDS Conference; July 7-14, 2002; Barcelona, Spain. TuPeC4724.
36. Mathews WC, McCutchan JA, Asch S, et al. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Med Care. 2000; 38(7):750-762.
37. Holzemer WL, Hudson A, Kirksey KM, Hamilton MJ, Bakken S. The revised Sign and Symptom Check-List for HIV (SSC-HIV rev). J Assoc Nurses AIDS Care. 2001; 12(5):60-70.
38. Ku JH, Kim MHE, Jeon YS, Lee NK, Park YH. Impact of urinary symptoms on bothersomeness and quality of life in young men. Urology. 2002; 60(3):442-448.
39. Bertaccini A, Vassallo F, Martino F, et al. Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH. Eur Urol. 2001;40(suppl 1):13-18.
40. Moller LA, Lose G, Jorgensen T. The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta Obstet Gynecol Scand. 2000; 79(4):298-305.
41. Vroomen PC, de Krom MC, Wilmink JT, Kester AD, Knottnerus JA. Lack of effectiveness of bed rest for sciatica. N Engl J Med. 1999; 340(6):418-423.
42. Sherman DW. The perceptions and experiences of patients with AIDS: implications regarding quality of life and palliative care. J Hosp Palliat Nurs. 2001; 3(1):7-16.
43. Armes PJ, Higginson IJ. What constitytes high-quality HIV/AIDS palliative care? J Palliat Care. 1999;15(4):5-12.
44. Holzemer WL. HIV and AIDS: the symptom experience. What cell counts and viral loads won’t tell you. Am J Nurs. 1999;102: 48-52.
45. Valente SM, Saunders JM, Uman G. Self-care, psychological distress, and HIV disease. J Assoc Nurses AIDS Care. 1993; 4(4):15-25.
46. Lee KA. Portillo CJ. Miramontes H. The influence of sleep and activity patterns on fatigue in women with HIV/AIDS. J Assoc Nurses AIDS Care. 2001;12(suppl):19-27.
47. Burgoyne RW, Saunders DS. Quality of life among urban Canadian HIV/AIDS clinic outpatients. Int J STD AIDS. 2001; 12(8):505-512.
48. Vosvick M, Koopman C, Gore-Felton C, Thorensen C, Krumboltz J, Spiegel D. Relationship of functional quality of life to strategies for coping with the stress of living with HIV/AIDS. Psychosomatics. 2003; 44(10):51-58.
49. Penedo FJ, Gonzalez JS, Dahn JR, et al. Personality, quality of life and HAART adherence among men and women living with HIV/AIDS. J Psychosom Res. 2003; 54(3):271-278.
50. Watanabe M, Nakano E, Ito S, Ogane K, Ikeda S. HIV therapy, self-defined symptoms and quality of life for HIV positive patients in Japan. XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain: MoPeB3297.
51. Sherman DW. Patients with acquired immune deficiency syndrome. In: Ferrell BR, Coyle N, eds. Textbook of Palliative Nursing. New York: Oxford University Press; 2001:467-500.
52. Van Servellen G, Chang B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS. 2002; 16(6):269-281.
53. Hinkin CH, Durvasula RS, Mason KI, et al. Differential predictors of HAART adherence as a function of gender. In: XIV International AIDS Conference; July7-12, 2002; Barcelona, Spain. WePeB5823.
54. Mannheimer S, Friedland G, Matts J, Child C, Chesny M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002; 4(8):1115-1121.
55. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002; 46(2):93-108.
56. Israelski D, Gore-Felton C, Power R, Koopman C. Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. Prev Med. 2001; 33(5):470-475.
57. Ferguson TF, Stewart KE, Funkhouser E, Tolson J, Westfall AO, Saag MS. Patient-perceived barriers to antiretroviral adherence: associations with race. AIDS Care. 2002; 14(5):607-617.
58. Murri R, Ammassari A, De Luca A, et al. Self-reported nonadherence with antiretroviral drugs predicts persistent condition. HIV Clin Trials. 2001; 2(4):323-329.
59. Hinkin CH, Castellon SA, Hardy DJ, et al. Predictors of medication adherence in HIV/AIDS. In: XIV International AIDS Conference. July 7-12, 2002; Barcelona, Spain. WePeB5828.
60. Cashen MS, Wantland DJ, Holzemer WL, et al. Impact of literacy skills in individuals with HIV. In: XV International AIDS Conference; July 11-17,2004; Bangkok, Thailand. D12832.
61. Kalichman SC, Catz S, Ramachandran B. Barriers to HIV/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. J Natl Med Assoc. 1999; 91(8):439-446.
62. McDonnell M, Turner J, Weaver MT. Antecedents of adherence to antituberculosis therapy. Public Health Nurs. 2001; 17(6):392-400.
63. Wagner GJ, Remien RH, Carballo-Dieguez A, Dolezal C. Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care. 2002; 14(1):105-109.
64. Eholie ESP, Bissagnene EBE, Ouimininga MOM, et al. Adherence to HAART and its principal determinants in the HIV infected adults in Abidjan (Cote d’Ivoire). In: XV International AIDS Conference. July 11-16, 2004; Bangkok, Thailand. WePeB5790.
65. Bouhnik AD, Chesny M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S149-S153.
66. Wood E, Montaner JSG, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ/JAMC. 2003; 169:656-661.
67. Corless IB, Bunch EH, Kemppainen JK, et al. Self-care for fatigue. Oncology Nursing Forum Online Exclusive. 2002;29(5):775.
68. Nicholas PK, Kemppainen JK, Holzemer WL, et al. Self-Care Management for Neuropathy in HIV Disease. AIDS Care. 2002; 14(6):763-771.
69. Holzemer WL, Henry SB, Nokes KM, et al. Validation of the sign and symptom check-list for persons living with HIV disease (SSC-HIV). J Adv Nurs. 1999; 30(5):1041-1049.
70. Cleary PD, Fowler FJ Jr, Weissman J, et al. Health-related quality of life in persons with acquired immune deficiency syndrome. Med Care. 1993; 31(7):569-580.
71. Souza KH, Holzemer WL, Henry SB, Slaughter R. Dimensions of health-related quality of life in persons living with HIV disease. J Adv Nurs. 1999; 29(1):178-187.
72. Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus infection: measurement by the medical Outcomes Study instrument. Ann Intern Med. 1992; 116:129-137.
73. Markowitz AJ, Rabow MW. Overcoming the False Dichotomy of “Curative” vs. “Palliative” Care for Late-Stage HIV/AIDS: “Let Me Live the Way I want to Live, Until I Can’t.” JAMA. 2004;291(4):492.
74. Duong M, Piroth L, Grappin M, et al. Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens. HIV Clin Trials. 2001; 2(2):128-135.
75. Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when CD4+ count is 0.200 to 0.350x 10(9) cells/L. Ann Intern Med. 2003; 139:810-816.